Press releases

6 Nov 2025

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

3 Nov 2025

U.S. FDA approves KYGEVVI[®] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

31 Oct 2025

BIMZELX[®] (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years

29 Oct 2025

UCB to unveil new data for RYSTIGGO[®▼]and ZILBRYSQ[®▼] for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

25 Oct 2025

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

14 Oct 2025

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

Press releases

Press releases

Search Press releases

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

U.S. FDA approves KYGEVVI[®] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

BIMZELX[®] (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years

UCB to unveil new data for RYSTIGGO[®▼]and ZILBRYSQ[®▼] for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

U.S. FDA approves KYGEVVI[®] (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

BIMZELX[®] (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years

UCB to unveil new data for RYSTIGGO[®▼]and ZILBRYSQ[®▼] for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

BIMZELX[®] (bimekizumab-bkzx) three year rheumatology data at ACR 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior

Choose a Country